Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

Completed · Phase 2

Conditions studied: Opioid-Related Disorders

In brief

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.

Key facts

Study ID

NCT00000344

Run by

National Institute on Drug Abuse (NIDA)

People needed

40

Expected to finish

2000-08-01

Last updated by the study team

2017-01-12

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

You may not qualify if…

• Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Where it is running

• Friends Research Institute — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.